

ASX RELEASE

2022 ANNUAL GENERAL MEETING RESULTS

Wellington, NZ, 18 August 2022: Volpara Health Technologies Limited (ASX: VHT) (ARBN 609 946 867) advises the results of the Twelfth Annual General Meeting held today.

As required by ASX Listing Rules Guidance Note 35, section 10, and recommended by section 6.4 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations all voting was conducted by a poll.

The resolutions passed by shareholders were:

Resolution 2: Re-election of John Pavlidis as a Director of the Company

"That John Pavlidis, who retires as a director of the Company by rotation in accordance with clause 20.5 of the Company's constitution and who is eligible for re-election, be re-elected as a director of the Company."

Resolution 3: Re-election of Ann Custin as a Director of the Company

"That Ann Custin, who was appointed by the directors of the Company as an additional director on 1 September 2021 in accordance with clause 20.4 of the Company's constitution, be re-elected as a director of the Company."

Resolution 4: Approval for issue of options to Ann Custin

"That, subject to Ann Custin's re-election as director under resolution 3, pursuant to, and in accordance with, ASX Listing Rule 10.14 and for all other purposes, shareholders approve the grant to Ann Custin, a director of the Company, of 450,000 options on the terms and conditions set out in the Explanatory Notes to the Notice of Meeting."

Resolution 5: Approval to fix the fees and expenses of the auditor

"That the directors of the Company be authorised to fix the fees and expenses of the auditor for the financial year ending 31 March 2023."

Details of the total number of votes cast in person or by a proxy holder are:

Resolutions	For	Against	Abstain
Resolution 2: Re-election of John Pavlidis as a Director	90,290,274	1,020,982	44,509
Resolution 3: Re-election of Ann Custin as a Director	84,071,330	176,319	7,162,216
Resolution 4: Approval for issue of options to Ann Custin	50,423,540	33,818,879	7,211,849
Resolution 5: Auditor's Remuneration	91,175,956	51,754	165,781

The analysis of proxies as received from Boardroom Limited, the company's share registry, is attached.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Teri Thomas, CEO

Volpara Health Technologies

teri.thomas@volparahealth.com

t: +64 4 499 6029

Hannah Howlett

WE Communications

WE-AUVolpara@we-worldwide.com

t: +61 407 933 437

About Volpara Health Technologies Limited (ASX:VHT)

Volpara Health Technologies is a global leader in the research and development of artificial intelligence for the early detection of breast cancer. Volpara's software provides clinicians feedback on breast density, compression, dose, and quality, enabling them to offer their patients personalised breast care and enhanced risk assessment.

Founded in 2009 on research originally conducted at the University of Oxford, Volpara has seen its technology and services used by customers and/or research projects in 40 countries. Volpara's ground-breaking work is supported by 100 patents, over 200 peer-reviewed publications, the most rigorous security certifications, and numerous trademarks and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, Volpara has raised A\$132 million. With offices in Seattle and Boston, Volpara is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com.

Volpara Health Technologies Limited
Annual General Meeting
Thursday, 18 August 2022
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
2. Re-election of John Pavlidis as a Director of the Company	Ordinary	90,290,274 98.09%	1,020,982 1.11%	738,641 0.80%	44,509	91,028,915 98.91%	1,005,982 1.09%	75,009	Carried
3. Re-election of Ann Custin as a Director of the Company	Ordinary	84,071,330 98.91%	176,319 0.21%	753,641 0.89%	7,162,216	84,824,971 99.79%	176,319 0.21%	7,177,716	Carried
4. Approval for issue of options to Ann Custin	Ordinary	50,423,540 59.36%	33,818,879 39.81%	709,238 0.83%	7,211,849	51,132,778 60.19%	33,818,879 39.81%	7,227,349	Carried
5. Approval to fix the fees and expenses of the auditor	Ordinary	91,175,956 99.11%	51,754 0.06%	770,015 0.84%	165,781	91,961,471 99.94%	51,754 0.06%	165,781	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.